HARBIN, China, June 22 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that it obtained a renewal of its license for the production its proprietary Sumei Slim Patch from Heilongjiang Provincial FDA, which will be effective through April of 2013. Categorized as a medical device, the document number for the renewed SFDA approval of the Sumei Slim Patch is 2640029.
The Sumei Slim Patch is one of the Company's best selling products, accounting for 22% of total revenues in 2008. It is marketed and sold as a natural way to lose weight and has been shown to be 76.9% effective in clinical trials. Active ingredients in the Sumei Slim Patch include plant volatile oils and saponins, a class of chemical compounds found to regulate and restrain excessive secretion of certain hormones in order to foster weight loss. The Sumei Slim Patch, which employs the theories of Traditional Chinese Medicine (TCM), has become a widely accepted weight loss product in China, Southeastern Asia, and in other countries and regions of the world. There are quite a few reputable pharmaceutical companies and beauty product companies that have been marketing similar weight loss products in patch form, such as the "Perfect Slim Patch" from L'Oreal. Since the beginning of 2008, China Sky One Medical has sold over 7 million units of its Slim Patch around the world.
"Clinical trials conducted by the Heilongjiang Province Hospital have shown that the Sumei Slim Patch is a highly effective medical device that is a safe and reliable method for treating obesity based on the World Health Organization (WHO) definition of that term," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "Obesity is a serious danger to the lives of millions of people around the world, with increased incidences of heart disease and diabetes attributed to those who are overweight. We look forward to working with new international distributors to further expand sales of the Sumei Slim Patch and help prevent the spread of obesity."
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio- Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .
Safe Harbor Statement
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
For more information, please contact: Company Contact: China Sky One Medical, Inc. Mr. Yu-Bo Hao, CFO Tel: +86-451-5399-4069 Email: email@example.com Investor Relations Contact: CCG Investor Relations Mr. Crocker Coulson, President Tel: +1-646-213-1915 Email: firstname.lastname@example.org Website:http://www.ccgirasia.com
|SOURCE China Sky One Medical, Inc.|
Copyright©2009 PR Newswire.
All rights reserved